Histopathological grading of pediatric ependymoma

Reproducibility and clinical relevance in European trial cohorts

David W. Ellison, Mehmet Kocak, Dominique Figarella-Branger, Giangaspero Felice, Godfraind Catherine, Torsten Pietsch, Didier Frappaz, Maura Massimino, Jacques Grill, James M. Boyett, Richard G. Grundy

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Background: Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/CNS9904) to assess both diagnostic concordance among five neuropathologists and the prognostic utility of histopathological variables, particularly tumor grading. Results: In phase 1, using WHO criteria and without first discussing any issue related to grading ependymomas, pathologists assessed and independently graded ependymomas from 3 of 4 trial cohorts. Diagnosis of grade II ependymoma was less frequent than grade III, a difference that increased when one cohort (CNS9204) was reassessed in phase 2, during which the pathologists discussed ependymoma grading, jointly reviewed all CNS9204 tumors, and defined a novel grading system based on the WHO classification. In phase 3, repeat independent review of two cohorts (SFOP/CNS9904) using the novel system was associated with a substantial increase in concordance on grading. Extent of tumor resection was significantly associated with progression-free survival (PFS) in SFOP and AIEOP, but not in CNS9204 and CNS9904. Strength of consensus on grade was significantly associated with PFS in only one trial cohort (AIEOP). Consensus on the scoring of individual histopathological features (necrosis, angiogenesis, cell density, and mitotic activity) correlated with PFS in AIEOP, but in no other trial. Conclusions: We conclude that concordance on grading ependymomas can be improved by using a more prescribed scheme based on the WHO classification. Unfortunately, this appears to have utility in limited clinical settings.

Original languageEnglish (US)
Article number7
JournalJournal of Negative Results in BioMedicine
Volume10
Issue number1
DOIs
StatePublished - Jun 2 2011

Fingerprint

Ependymoma
Pediatrics
Disease-Free Survival
Tumors
Neoplasm Grading
Pathology
Neoplasms
Necrosis
Cell Count

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Histopathological grading of pediatric ependymoma : Reproducibility and clinical relevance in European trial cohorts. / Ellison, David W.; Kocak, Mehmet; Figarella-Branger, Dominique; Felice, Giangaspero; Catherine, Godfraind; Pietsch, Torsten; Frappaz, Didier; Massimino, Maura; Grill, Jacques; Boyett, James M.; Grundy, Richard G.

In: Journal of Negative Results in BioMedicine, Vol. 10, No. 1, 7, 02.06.2011.

Research output: Contribution to journalArticle

Ellison, DW, Kocak, M, Figarella-Branger, D, Felice, G, Catherine, G, Pietsch, T, Frappaz, D, Massimino, M, Grill, J, Boyett, JM & Grundy, RG 2011, 'Histopathological grading of pediatric ependymoma: Reproducibility and clinical relevance in European trial cohorts', Journal of Negative Results in BioMedicine, vol. 10, no. 1, 7. https://doi.org/10.1186/1477-5751-10-7
Ellison, David W. ; Kocak, Mehmet ; Figarella-Branger, Dominique ; Felice, Giangaspero ; Catherine, Godfraind ; Pietsch, Torsten ; Frappaz, Didier ; Massimino, Maura ; Grill, Jacques ; Boyett, James M. ; Grundy, Richard G. / Histopathological grading of pediatric ependymoma : Reproducibility and clinical relevance in European trial cohorts. In: Journal of Negative Results in BioMedicine. 2011 ; Vol. 10, No. 1.
@article{8d4dbac48a5e4ec980783c92f634b85b,
title = "Histopathological grading of pediatric ependymoma: Reproducibility and clinical relevance in European trial cohorts",
abstract = "Background: Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/CNS9904) to assess both diagnostic concordance among five neuropathologists and the prognostic utility of histopathological variables, particularly tumor grading. Results: In phase 1, using WHO criteria and without first discussing any issue related to grading ependymomas, pathologists assessed and independently graded ependymomas from 3 of 4 trial cohorts. Diagnosis of grade II ependymoma was less frequent than grade III, a difference that increased when one cohort (CNS9204) was reassessed in phase 2, during which the pathologists discussed ependymoma grading, jointly reviewed all CNS9204 tumors, and defined a novel grading system based on the WHO classification. In phase 3, repeat independent review of two cohorts (SFOP/CNS9904) using the novel system was associated with a substantial increase in concordance on grading. Extent of tumor resection was significantly associated with progression-free survival (PFS) in SFOP and AIEOP, but not in CNS9204 and CNS9904. Strength of consensus on grade was significantly associated with PFS in only one trial cohort (AIEOP). Consensus on the scoring of individual histopathological features (necrosis, angiogenesis, cell density, and mitotic activity) correlated with PFS in AIEOP, but in no other trial. Conclusions: We conclude that concordance on grading ependymomas can be improved by using a more prescribed scheme based on the WHO classification. Unfortunately, this appears to have utility in limited clinical settings.",
author = "Ellison, {David W.} and Mehmet Kocak and Dominique Figarella-Branger and Giangaspero Felice and Godfraind Catherine and Torsten Pietsch and Didier Frappaz and Maura Massimino and Jacques Grill and Boyett, {James M.} and Grundy, {Richard G.}",
year = "2011",
month = "6",
day = "2",
doi = "10.1186/1477-5751-10-7",
language = "English (US)",
volume = "10",
journal = "Journal of Negative Results in BioMedicine",
issn = "1477-5751",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Histopathological grading of pediatric ependymoma

T2 - Reproducibility and clinical relevance in European trial cohorts

AU - Ellison, David W.

AU - Kocak, Mehmet

AU - Figarella-Branger, Dominique

AU - Felice, Giangaspero

AU - Catherine, Godfraind

AU - Pietsch, Torsten

AU - Frappaz, Didier

AU - Massimino, Maura

AU - Grill, Jacques

AU - Boyett, James M.

AU - Grundy, Richard G.

PY - 2011/6/2

Y1 - 2011/6/2

N2 - Background: Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/CNS9904) to assess both diagnostic concordance among five neuropathologists and the prognostic utility of histopathological variables, particularly tumor grading. Results: In phase 1, using WHO criteria and without first discussing any issue related to grading ependymomas, pathologists assessed and independently graded ependymomas from 3 of 4 trial cohorts. Diagnosis of grade II ependymoma was less frequent than grade III, a difference that increased when one cohort (CNS9204) was reassessed in phase 2, during which the pathologists discussed ependymoma grading, jointly reviewed all CNS9204 tumors, and defined a novel grading system based on the WHO classification. In phase 3, repeat independent review of two cohorts (SFOP/CNS9904) using the novel system was associated with a substantial increase in concordance on grading. Extent of tumor resection was significantly associated with progression-free survival (PFS) in SFOP and AIEOP, but not in CNS9204 and CNS9904. Strength of consensus on grade was significantly associated with PFS in only one trial cohort (AIEOP). Consensus on the scoring of individual histopathological features (necrosis, angiogenesis, cell density, and mitotic activity) correlated with PFS in AIEOP, but in no other trial. Conclusions: We conclude that concordance on grading ependymomas can be improved by using a more prescribed scheme based on the WHO classification. Unfortunately, this appears to have utility in limited clinical settings.

AB - Background: Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/CNS9904) to assess both diagnostic concordance among five neuropathologists and the prognostic utility of histopathological variables, particularly tumor grading. Results: In phase 1, using WHO criteria and without first discussing any issue related to grading ependymomas, pathologists assessed and independently graded ependymomas from 3 of 4 trial cohorts. Diagnosis of grade II ependymoma was less frequent than grade III, a difference that increased when one cohort (CNS9204) was reassessed in phase 2, during which the pathologists discussed ependymoma grading, jointly reviewed all CNS9204 tumors, and defined a novel grading system based on the WHO classification. In phase 3, repeat independent review of two cohorts (SFOP/CNS9904) using the novel system was associated with a substantial increase in concordance on grading. Extent of tumor resection was significantly associated with progression-free survival (PFS) in SFOP and AIEOP, but not in CNS9204 and CNS9904. Strength of consensus on grade was significantly associated with PFS in only one trial cohort (AIEOP). Consensus on the scoring of individual histopathological features (necrosis, angiogenesis, cell density, and mitotic activity) correlated with PFS in AIEOP, but in no other trial. Conclusions: We conclude that concordance on grading ependymomas can be improved by using a more prescribed scheme based on the WHO classification. Unfortunately, this appears to have utility in limited clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=79957639069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957639069&partnerID=8YFLogxK

U2 - 10.1186/1477-5751-10-7

DO - 10.1186/1477-5751-10-7

M3 - Article

VL - 10

JO - Journal of Negative Results in BioMedicine

JF - Journal of Negative Results in BioMedicine

SN - 1477-5751

IS - 1

M1 - 7

ER -